{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:55:45Z","timestamp":1793778945716,"version":"4.6.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T00:00:00Z","timestamp":1733788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Psoriasis is a chronic, immune-mediated inflammatory skin disease that significantly impacts patients\u2019 quality of life. The integration of telepharmacy has the potential to enhance patient care by providing flexible and personalized pharmaceutical follow-up. This study (TELEPROM Psoriasis) evaluates a telepharmacy model for evaluating electronic Patient-Reported outcomes (ePROMs) for individuals with moderate to severe plaque psoriasis in Spain with biological treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental approach<\/jats:title><jats:p>This multicenter prospective quasi-experimental study included 258 adult patients initiating or switching biological\/immunomodulatory therapy for moderate to severe plaque psoriasis. Patients were recruited from public hospitals in Spain and monitored through the NAVETA telepharmacy platform over a six-month period. PROMs assessed were the Psoriasis Symptoms and Signs Diary and the Dermatology Life Quality Index at baseline, 1\u202fmonth, 3\u202fmonths, and 6\u202fmonths. Data were analyzed using ANOVA, Student\u2019s <jats:italic>t<\/jats:italic>-test, multiple regression, and machine learning algorithms to evaluate ePROMs evolution and response and satisfaction with Telepharmacy follow up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key results<\/jats:title><jats:p>The analysis revealed significant influences of gender, employment status, educational level, and daily activity, but no effect of age, on responses to Patient-Reported Outcomes questionnaires. Machine learning models, particularly Random Forest (AUC\u202f=\u202f0.98) and Support Vector Machine (AUC\u202f=\u202f0.96), effectively predicted patient engagement. DLQI scores significantly decreased from 9.33\u202f\u00b1\u202f7.75 at baseline to 4.34\u202f\u00b1\u202f5.86 at 6\u202fmonths. Similarly, the PSSD - 7\u202fDays questionnaire showed major reductions, with scores dropping from 55.43\u202f\u00b1\u202f29.94 to 30.73\u202f\u00b1\u202f30.66 at 6\u202fmonths, and 53% of patients reaching a score of 20 or less. Notably, women reported worse scores at all time points compared to men. Regression analysis explained only 13.2% of the variance in PROMs scores, identifying Employment Status and BMI Range as key contributors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study demonstrates the efficacy of biologic treatments in significantly improving HRQoL for psoriasis patients. Addressing demographic variables, such as gender, is key for optimizing treatment outcomes and improving ePROMs response rates. Tailored strategies and ML techniques can help identify low-engagement patients and mitigate disparities. Integrating sociodemographic factors into clinical decision-making and patient engagement strategies is fundamental for delivering equitable and comprehensive care.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1465725","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T12:00:18Z","timestamp":1733832018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["TELEPROM Psoriasis: Enhancing patient-centered care and health-related quality of life (HRQoL) in moderate-to-severe plaque psoriasis"],"prefix":"10.3389","volume":"11","author":[{"given":"Gabriel","family":"Mercadal-Orfila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piedad","family":"L\u00f3pez S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aranzazu","family":"Pou Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatz","family":"Ibarra-Barrueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Monte-Boquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin","family":"Borr\u00e1s Blasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Padull\u00e9s Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sanmartin-Fenollera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Capilla Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. \u00c1ngeles","family":"Bernab\u00e9u Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Herrera-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.ad.2017.07.002","article-title":"Moderate psoriasis: a proposed definition","volume":"108","author":"Llamas-Velasco","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.ad.2012.04.005","article-title":"Clinical and therapeutic evaluation of patients with moderate to severe psoriasis in Spain: the Secuence study","volume":"103","author":"Hern\u00e1nz","year":"2012","journal-title":"Actas Dermosifiliogr"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"11574","DOI":"10.3390\/ijms222111574","article-title":"Current concepts of psoriasis Immunopathogenesis","volume":"22","author":"Vi\u010di\u0107","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"687","DOI":"10.2147\/BTT.S2763","article-title":"Biological drugs targeting the immune response in the therapy of psoriasis","volume":"2","author":"Korkina","year":"2008","journal-title":"Biologics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.ad.2013.03.005","article-title":"Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: the VACAP study","volume":"104","author":"Daud\u00e9n","year":"2013","journal-title":"Actas Dermosifiliogr"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1159\/000528945","article-title":"Patient perspectives on psoriatic disease Burden: results from the global psoriasis and beyond survey","volume":"239","author":"Armstrong","year":"2023","journal-title":"Dermatology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s00403-023-02566-w","article-title":"Patients\u2019 perspectives towards biologic dose reduction in psoriasis: a qualitative study","volume":"315","author":"Van Der Schoot","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e56196","DOI":"10.2196\/56196","article-title":"Implementing systematic patient-reported measures for chronic conditions through the Naveta value-based telemedicine initiative: observational retrospective multicenter study","volume":"12","author":"Mercadal-Orfila","year":"2024","journal-title":"JMIR Mhealth Uhealth"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e15588","DOI":"10.2196\/15588","article-title":"Benefits and disadvantages of electronic patient-reported outcome measures: systematic review","volume":"3","author":"Meirte","year":"2020","journal-title":"JMIR Perioper Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.35680\/2372-0247.1664","article-title":"Current PROM and PREM use in health system performance measurement: still a way to go","volume":"9","author":"Bull","year":"2022","journal-title":"Patient Exp J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1007\/s00296-021-04863-x","article-title":"Use of telemedicine during the COVID-19 pandemic in patients with inflammatory arthritis: a retrospective study on feasibility and impact on patient-reported outcomes in a real-life setting","volume":"41","author":"Chevallard","year":"2021","journal-title":"Rheumatol Int"},{"key":"ref14","first-page":"115","article-title":"Implementation of pharmaceutical care through Telepharmacy: a guide for professionals and patients","volume":"46","author":"Morillo-Verdugo","year":"2022","journal-title":"Farm Hosp"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40545-023-00538-z","article-title":"Telepharmacy during home isolation: drug-related problems and pharmaceutical care in COVID-19 patients receiving antiviral therapy in Thailand","volume":"16","author":"Sungsana","year":"2023","journal-title":"J Pharm Policy Pract"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"adv00559","DOI":"10.2340\/00015555-3884","article-title":"Patient-reported outcome measures in dermatology: a systematic review","volume":"101","author":"Pattinson","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/bjd.13775","article-title":"Patient-reported outcome measures in psoriasis: assessing the assessments","volume":"172","author":"Finlay","year":"2015","journal-title":"Br J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdds.2015.07.004","article-title":"Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the psoriasis symptoms and signs diary","volume":"20","author":"Feldman","year":"2016","journal-title":"J Dermatol Dermat Surg"},{"key":"ref19","first-page":"692","article-title":"Adaptaci\u00f3n transcultural al espa\u00f1ol del cuestionario Dermatology Life Quality Index (DLQI): El \u00cdndice de Calidad de Vida en Dermatolog\u00eda","volume":"89","author":"de Tiedra","year":"1998","journal-title":"Actas Dermosifiliogr"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/09546634.2017.1364694","article-title":"Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial","volume":"30","author":"Armstrong","year":"2019","journal-title":"J Dermatol Treat"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s13555-021-00545-5","article-title":"Dermatology life quality index in patients with moderate-to-severe plaque psoriasis treated with Brodalumab or Ustekinumab","volume":"11","author":"Lambert","year":"2021","journal-title":"Dermatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.4103\/picr.picr_38_24","article-title":"Handling missing data in research","volume":"15","author":"Ranganathan","year":"2024","journal-title":"Perspect Clin Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"385","DOI":"10.4103\/0019-5154.185700","article-title":"Biostatistics series module 4: comparing groups - categorical variables","volume":"61","author":"Hazra","year":"2016","journal-title":"Indian J Dermatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e0267931","DOI":"10.1371\/journal.pone.0267931","article-title":"Using machine learning to predict health-related quality of life outcomes in patients with low grade glioma, meningioma, and acoustic neuroma","volume":"17","author":"Karri","year":"2022","journal-title":"PLoS One"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.3390\/diagnostics13101692","article-title":"Impact of cross-validation on machine learning models for early detection of intrauterine fetal demise","volume":"13","author":"Kaliappan","year":"2023","journal-title":"Diagnostics"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12931-021-01690-3","article-title":"Development and performance assessment of novel machine learning models to predict pneumonia after liver transplantation","volume":"22","author":"Chen","year":"2021","journal-title":"Respir Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1111\/jdv.19800","article-title":"Estimating meaningful change thresholds for skin pain-numeric rating scale, sleep-numeric rating scale and dermatology life quality index in patients with prurigo nodularis","volume":"38","author":"Stander","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1001\/jamadermatol.2023.5058","article-title":"Meaningful change thresholds for the psoriasis symptoms and signs diary: a secondary analysis of a randomized clinical trial","volume":"160","author":"Papp","year":"2024","journal-title":"JAMA Dermatol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.7717\/peerj-cs.623","article-title":"The coefficient of determination R-squared is more informative than SMAPE, MAE, MAPE, MSE and RMSE in regression analysis evaluation","volume":"7","author":"Chicco","year":"2021","journal-title":"PeerJ Comput Sci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ad.2016.04.018","article-title":"The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review","volume":"107","author":"Burgos-Pol","year":"2016","journal-title":"Actas Dermosifiliogr"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"T204","DOI":"10.1016\/j.farma.2024.04.012","article-title":"Perceived quality of life in patients with psoriasis treated with interleukin 17 or 23 inhibitors","volume":"48","author":"Anguita-Montenegro","year":"2024","journal-title":"Farm Hosp"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jhqr.2023.10.004","article-title":"Incorporation of patient-reported outcomes into pharmacy and dermatology departments, in psoriasis and atopic dermatitis patients, as a tool to improve the healthcare quality and health outcomes","volume":"39","author":"Gonz\u00e1lez-Fern\u00e1ndez","year":"2024","journal-title":"J Healthc Qual Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12874-021-01419-2","article-title":"Response rate of patient reported outcomes: the delivery method matters","volume":"21","author":"Neve","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s41687-019-0121-6","article-title":"Response rate and costs for automated patient-reported outcomes collection alone compared to combined automated and manual collection","volume":"3","author":"Pronk","year":"2019","journal-title":"J Patient Rep Outcomes"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/bjd.16776","article-title":"Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study","volume":"180","author":"Warren","year":"2019","journal-title":"Br J Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"e0237267","DOI":"10.1371\/journal.pone.0237267","article-title":"Patients\u2019 demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis","volume":"15","author":"Scala","year":"2020","journal-title":"PLoS One"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.pec.2022.01.008","article-title":"The association between patient-reported outcomes (PROs) and patient participation in chronic care: a scoping review","volume":"105","author":"Eriksen","year":"2022","journal-title":"Patient Educ Couns"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","article-title":"Biologics can significantly improve dermatology life quality index (DLQI) in psoriatic patients: a systematic review","volume":"12","author":"De Ruiter","year":"2022","journal-title":"Psoriasis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"2231847","DOI":"10.1080\/07853890.2023.2231847","article-title":"Life quality among psoriasis patients based on dermatology life quality index evaluation and its association with psoriasis severity in China: a cross-sectional study","volume":"55","author":"Chen","year":"2023","journal-title":"Ann Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40801-023-00359-1","article-title":"Dermatology life quality index in patients with psoriasis treated with biologic versus non-biologic treatment in Malaysia: a retrospective cross-sectional study","volume":"10","author":"Robinson","year":"2023","journal-title":"Drugs Real World Outcomes"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"T33","DOI":"10.1016\/j.ad.2022.07.025","article-title":"[Art\u00edculo traducido] Calidad de vida y regi\u00f3n corporal afectada por la psoriasis: una revisi\u00f3n sistem\u00e1tica","volume":"114","author":"Nabieva","year":"2023","journal-title":"Actas Dermosifiliogr"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"12","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40257-018-0396-z","article-title":"Improvement in patient-reported outcomes (dermatology life quality index and the psoriasis symptoms and signs diary) with Guselkumab in moderate-to-severe plaque psoriasis: results from the phase III VOYAGE 1 and VOYAGE 2 studies","volume":"20","author":"Armstrong","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"adv20329","DOI":"10.2340\/actadv.v104.20329","article-title":"Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis: a cross-sectional global healthcare study on psoriasis","volume":"104","author":"Maul","year":"2024","journal-title":"Acta Derm Venereol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2340\/00015555-2833","article-title":"Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with Ustekinumab","volume":"98","author":"Hesselvig","year":"2018","journal-title":"Acta Derm Venereol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1465725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T12:00:23Z","timestamp":1733832023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1465725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":45,"alternative-id":["10.3389\/fmed.2024.1465725"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1465725","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"article-number":"1465725"}}